Trials that use: Risk difference
New to this method? Read the tutorial →
6,276 results
- Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP): Complete Statistical AnalysisIndependent statistical analysis of Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00356993).
- Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02047500).
- Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas: Complete Statistical AnalysisIndependent statistical analysis of Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01434602).
- Phase I/II Calcitriol in Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Calcitriol in Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00794547).
- Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: primary endpoint results,…
- Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: primary endpoint results, effect estimate with confidence…
- Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03023722).
- Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Dasatinib Study in Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Dasatinib Study in Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00546104).
- Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Neoadjuvant in Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Neoadjuvant in Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00756470).
- Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): Complete Statistical AnalysisIndependent statistical analysis of Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00379197).
- Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: primary endpoint results, effect estimate…
- Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Doxorubicin and Avastin® in Sarcoma.: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Doxorubicin and Avastin® in Sarcoma.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00755261).
- Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: primary endpoint results,…
- Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval,…
- Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Study of TAK228 in Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of TAK228 in Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02727777).
- Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05068752).
- Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01827371).
- Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10: Complete Statistical AnalysisIndependent statistical analysis of Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02329730).
- Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas: Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size…
- Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China: Complete Statistical AnalysisIndependent statistical analysis of Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase l/II Study of Ruxolitinib for Acute Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase l/II Study of Ruxolitinib for Acute Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01251965).